VIP 10mg
Full-Protocol VIP for Comprehensive Immunomodulatory Research
The 10mg VIP vial provides double the compound for comprehensive pulmonary, autoimmune, and neuroprotective research protocols.
Full-Protocol VIP for Comprehensive Immunomodulatory Research
Same vasoactive intestinal peptide at double the quantity for extended VPAC receptor research, autoimmune disease studies, and pulmonary hypertension protocol replication.
As one of the most studied compounds in the recovery & healing research space, VIP has attracted sustained scientific interest across Extended pulmonary research, Comprehensive autoimmune studies. Peer-reviewed evidence indicates that double supply for comprehensive protocols, which has positioned VIP as a reference standard for researchers exploring extended pulmonary research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
VIP Documented Benefits: 1 Documented Mechanisms
Extended Protocol Supply
Double the 5mg vial for comprehensive VIP mechanism and disease model studies.
How VIP Works: Molecular Mechanism & Pathway
Same VIP VPAC1/VPAC2 agonist cAMP/PKA anti-inflammatory and smooth muscle relaxation mechanism.
The 1 primary research pathways identified for VIP — Extended Protocol Supply — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that 99%+ purity, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, VIP's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
VIP is routinely studied alongside KPV and LL-37 in recovery & healing-focused compound panels. Researchers investigating extended pulmonary research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that enables full dose-response studies has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All VIP research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Double supply for comprehensive protocols
- 99%+ purity
- Enables full dose-response studies
Ideal For
- Extended pulmonary research
- Comprehensive autoimmune studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on VIP. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Double supply for comprehensive protocols
99%+ purity
Enables full dose-response studies
Third-Party Verified Every Batch
Each vial of VIP is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
